Two-year efficacy and safety of simvastatin 80 mg in familial hypercholesterolemia (the Examination of Probands and Relatives in Statin Studies with Familial Hypercholesterolemia [ExPRESS FH])

American Journal of Cardiology

Volumn 90, Issue 2, 2002, Pages 181-184

  De Sauvage Nolting, Pernette R W ^a,b   Buirma, Rudolf J A ^b   Hutten, Barbara A ^c   Kastelein, John J P ^a  

^a Department of Vascular Medicine ^*  (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c NV ORGANON   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; CREATINE KINASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERANCE; DRUG WITHDRAWAL; ENZYME BLOOD LEVEL; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HUMAN; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; MYOPATHY; PATIENT COMPLIANCE; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME;

ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS; CREATINE KINASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPOPROTEINS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; MUSCULAR DISEASES; SIMVASTATIN; TIME FACTORS; TRANSAMINASES; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 0037099283     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(02)02449-9     Document Type: Article

References (6)

1. Familial hypercholesterolemia
2. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
3. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B
4. Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands
5. Development of tachyphylaxis among patients taking HMG CoA reductase inhibitors
6. Lipid-altering efficacy and safety of simvastatin 80 mg/day: Worldwide long-term experience in patients with hypercholesterolemia